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Soraya Carrancio,2 Carmen Herrero,2 Bele´n Blanco,2 Silvia Gutierrez-Cosio,2
Cristina Can˜ete-Campos,1 Fernando Cruz Gonza´lez,1 Jesus F. San-Miguel,2,4,5,6
Emiliano Herna´ndez-Galilea,1 Ignacio Sa´nchez-Abarca2,4,5Graft-versus-host disease (GVHD) is the major cause of morbidity and mortality among patients undergoing
allogeneic hematopoietic stem cell transplantation. Although animal models have been clearly established for
the study of skin, liver, and gut, currently there is no equivalent experiemental model for analyzing ocular
involvement, which is rather common, especially among patients diagnosed with chronic GVHD. In the
current study we have developed a murine model of ocular GVHD and, for the first time, we describe
the histopathologic features involving cornea and limbus, which could play a role in the physiopathology
of the disease at the ocular level. Our results represent a major finding that allows us to define a model
for evaluating new therapeutic strategies for treating ocular GVHD prior to their use in clinical setting.
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Graft-versus-hostdisease (GVHD) is themajor cause
of morbidity and mortality among patients undergoing
allogeneic hematopoetic stem cell transplantation
(HSCT) [1-3]. Among target organs, ocular in-
volvement has been reported in up to 60% of patients
[4,5]. Although it mostly appears in the chronic GVHD
(cGVHD) setting, it can also be a manifestation of
acute GVHD (aGVHD) [2,6]. Ocular GVHD affects
all layers of the eye, but the most commonly affected is
the ocular surface [7]. The ophthalmic clinical features
include keratoconjunctivitis sicca, punctate keratophaty,
persistent epithelial defects, corneal keratinization, ulcer-
ation, and perforation [8]. Posterior segment manifesta-
tions are less frequent and include microvascular
retinopathy, intraretinal and vitreous hemorrhage, cen-
tral serous chorioretinopathy, and scleritis. GVHD also1Servicio de Oftalmologı´a; 2Servicio de Hematologı´a;
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6/j.bbmt.2010.08.008affects the eyelids, causing dermatitis, lagophthalmos,
ectropion, poliosis, madarosis, and vitiligo [8-11]. Dry
eye is the main ophthalmologic complication among
patients with cGVHD [12], and although several
treatments have been used to minimize its symptoms,
therapeutic options are limited [13-15]. Furthermore,
although ocular involvement does not affect the
outcome of the patients with respect to mortality,
different studies on quality of life recognize this
complication as being a major concern [2,3,5,15,16].
Despite its impact on the morbidity associated
with transplant, the histopathology of ocular involve-
ment is not well understood, because most studies
have focused on clinical manifestations. A few reports
have examined ocular histopathology in GVHD, de-
scribing the histologic features in the conjunctiva
and lachrymal glands [14,17,18]. Nevertheless, the
histopathology of the cornea and limbus continues to
lack thorough examination [7,8,19], mainly because
there are no animal models that allow us to determine
the involvement of these layers with greater accuracy.
The current study establishes a murine model of
GVHD and describes for the first time the histopatho-
logic features involving cornea and limbus that explain
many of the clinical characteristics of this syndrome.MATERIALS AND METHODS
Animals
All animal protocols were approved by the Univer-
sity of Salamanca Animal Care and Use Committee.
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were purchased from Charles River Laboratory,
France. Animals were kept in specific pathogen-free
conditions. Mice were between 8 and 12 weeks of
age at the beginning of the experiments. Donor mice
were killed by cervical dislocation, and their bone
marrow (BM) and spleen from C57BL/6 were then
harvested by standard techniques. Spleen cell prepara-
tions were prepared by gently crushing the tissues to
release the cells. Preparations were filtered to remove
debris and washed twice in phosphate-buffered saline
(PBS) before injection.
BALB/c (H2d) mice were used as recipients in the
GVHD model systems. Recipient mice received total
body irradiation (TBI) (850 cGy divided into 2 frac-
tions) from a Cs source. Irradiation was followed by
the infusion of 5  106 C57BL/6 allogeneic donor
BM cells intravenously with or without splenocytes
(5-10  106 cells intravenously) as a source of alloge-
neic T cells. Mice were monitored and weighed twice
a week. All moribund mice were humanely killed.
The degree of systemic GVHD was assessed by
a standard scoring system from 0 to 2, which incorpo-
rates 5 clinical traits: weight loss, posture (hunching),
activity, fur texture, and skin integrity [20]. Three
clinical features of the eyes were also monitored: peri-
ocular fur, eyelid margin, and blepharospasm. Each
characteristic was scored between 0 (no loss of perioc-
ular fur, no crusting of the eyelid margin/erythema-
tous lids, no blepharospasm), 1 (1 feature of the
following: loss of periocular fur, crusting of the eyelid
margin/erythematous lids, blepharospasm), and 2 (2 or
3 of the previously mentioned features). Transplanted
mice were ear-punched, and individual weights were
recorded on day 0 and weekly thereafter. At the time
of analysis, mice from coded cages were evaluated
and graded for each criterion.
Mice were killed 2 months after allogeneic HSCT
by CO2 asphyxiation followed by cervical dislocation.
Afterward we removed the right and left eyes, lachry-
mal glands, and eyelids. We also analyzed portions of
skin, liver, and intestine.
The enucleated eyes, eyelids, and lachrymal glands
were fixed in neutral buffered formalin and embedded
in paraffin. The eyes were then sectioned sagitally
through the optic nerve and processed for hematoxylin-
eosin staining.Pathological Examination
Slides were coded and examined by a trained pa-
thologist. Eye specimens were routinely processed
and embedded in paraffin and serially sectioned. Slides
were then deparaffinized and rehydrated. After gentle
washing, the slides were stained with hematoxylin for
5 minutes, washed again, and stained with eosin for 1
minute. Samples were then dehydrated in 95% ethanolto remove excess eosin. Finally, slides were dried in
xylene overnight.
The pathologist analyzed the features of GVHD
present in gut, liver, and skin as well as those most
commonly reported in the conjunctiva and lachrymal
gland of the human eye [19,21,22]. Apoptosis was
ascertained by assessing the presence of chromatin
clumping, nuclear pyknosis, or nuclear debris and was
confirmed using caspase 3 (Novocastra Lyophilized
Mouse Monoclonal Antibody CPP32).RESULTS AND DISCUSSION
Allmice receiving donor splenocytes exhibited clin-
ical features $1 of GVHD 30-60 days after allogeneic
BM transplantation: weight loss, hunched posture,
abnormal fur texture, poor skin integrity, and decreased
activity. External ocular findings included (1) loss of
periocular fur, (2) crusting of the eyelid margin or ery-
thematous lids, and (3) blepharospasm. Control mice
receiving donor BMcells intravenouslywithout spleno-
cytes were also sacrified the same day postransplant as
those developing GVHD and were used as controls.
Histopathologic examination of gut, liver, and skin
showed signs ofGVHD.Macroscopical examination of
the enucleated eyes showed corneal ulcers (Figure 1B).
Pathologic examination revealed the presence of histo-
logic features of GVHD. Thus, eyelid biopsies showed
a lymphocytic infiltrate at the dermal and epidermal
junction with vacuolization of epidermal cells. Satelli-
tosis, that is, lymphocytes surrounding apoptotic
epidermal keratinocytes, were observed.We also found
apoptosis among basilar keratinocytes. All these data
provided evidence of GVHD-induced dermatitis.
Lachrymal gland specimens showed eosinophilic
focal infiltration in the interlobular area in 8 of 10
sections analyzed, whereas there were no mononuclear
cells in the acinar area. A number of eosinophils
appeared to infiltrate the ductal epithelia, and apopto-
tic bodies were also observed. Finally, fibrosis was
observed surrounding lachrymal gland ducts.
The corneal epithelium was atrophic and showed
vacuolization of the epithelial cells of the basal and
medium layers of the cornea. Two or more apoptotic
cells with infiltrating leukocytes were also observed
in corneal epithelium in at least 8 of 10 sections
analyzed. Furthermore, difuse stromal edema with
neovascularization and inflammatory infiltrate was
observed. No significant abnormalities were observed
in the endothelium (Figure 1).
In bulbar and tarsal conjunctiva we observed dys-
keratosis with loss of conjunctival epithelium, lympho-
cyte exocytosis, satellitosis, and epithelial cell necrosis,
with apoptotic bodies in the epithelium in 8 of 8 sam-
ples analyzed. Subepithelial microvesicles and mono-
nuclear cells infiltrating the substantia propia were
Figure 1. Light microscopic findings of cornea in mice with ocular GVHD. Hematoxylin and eosin staning. Original magnification 40. (A) Shows cy-
toplasmic vacuolization in the basal layer of the epithelium (arrow) and stromal edema of the cornea (blue arrow). (B) A high magnification view of A
shows a detail of vacuolization cells with apoptotic bodies and satellitosis of the cornea. (C) Epithelial necrosis of the cornea showing apoptotic bodies
(arrow) and stromal and epithelial inflammatory infiltrate. (D) Corneal stromal vascularization (arrow), edema, and lymphomononuclear cell infiltrate.
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(Figure 2).
Notably, limbus epithelium showed the same
histologic features as those observed in corneal epithe-
lium, with satellitosis, vacuolization of cells, and pres-
ence of apoptotic bodies as suggested by the presence
of chromatin clumpings and nuclear pyknosis in at
least 8 out of 10 biopsies analyzed. In addition, edema
of corneal stroma was also observed (Figure 3).
None of the findings were found, neither in the
external nor in the histopathologic examination among
control mice receiving TBI plus BM cells. Accordingly,
all these features are specific for GVHD and not for
stress, TBI, or other nonspecific causes.Figure 2. (A) Light microscopic findings of conjunctiva with macroscopic ocu
tory infiltration of the conjunctiva and slight lymphomononuclear cell infiltrate
ent at the corneal epithelium, (shown as chromatin clumpings and nuclear pykn
confirming the presence of apoptotic bodies in the conjunctiva.GVHD is a complex immunologic process that
involves several organs. Ocular manifestations are
found in the majority of patients and have been
reported in up to 80% of patients with cGVHD [7].
Although less frequent, ocular damage has also been
described in the aGVHD setting.
Although the transplant model used in the current
study is widely used, ocular involvement has not been
previously reported. Accordingly, our results represent
amajor finding that allows amodel of ocular GVHD to
be established. In this regard, although histopathologic
findings have already been described in other target
organs, this is not the case for cornea and limbus and,
furthermore, an animal model has not been previouslylar GVHD. Hematoxylin and eosin staning. This view shows an inflamma-
of the sclera (blue arrow). A focal apoptotic bodies formations are pres-
osis) (black arrow) (original magnification,100). (B) Caspase 3 staining
Figure 3. Histologic changes from esclerocorneal limbus of mouse with ocular GVHD. (A) This view shows the damage at epithelial layer, including
lymphocyte exocytosis and presence of mononuclear cells at the superficial layers of the epithelium (black arrow), with pronounced lymphomonocytic
and eosinophil inflammatory infiltrate with stromal edema of limbus (blue arrow) (original magnification,40). (B) This high magnification view (original
magnification, 100) shows a detail of vacuolization of the limbar cells (arrow).
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new therapeutic strategies prior to their use in the clin-
ical setting. Furthermore, the current study allowed us
to analyze more accurately the pathologic findings in
ocular GVHD. It has not previously been possible to
explore these because of the lack of a clearly established
animal model. In fact, several findings have already
been reported, especially those affecting lachrymal
glands, conjunctiva, eyelids and, to a lesser extent,
cornea [15-18]. Nevertheless, in the current study we
have shown that ocular GVHD also involves cornea
and limbus, which show histopathologic findings
similar to those observed in other target organs.
In conclusion, the current study establishes an
animal model for the evaluation of ocular GVHD
and identifies limbus as a target organ.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-
versus-host syndrome in man: a long term clinicopathologic
study of 20 Seattle patients. Am J Med. 1980;69:204-217.
2. Mencucci R, Ferrini CR, Bosi A, Volpe R, Guidi S, Salvi G.
Ophthalmological aspects in allogenic bone marrow transplan-
tation: Sjo¨gren-like syndrome in graft-versus host disease.
Eur J Ophthalmol. 1997;7:13-18.
3. Tichelli A,DuellT,WeissM, et al. Late onset keratoconjunctivits
sicca syndrome after bone marrow transplantation: incidence and
risk factors. Bone Marrow Transplant. 1996;17:1105-1111.
4. Franklin RM, KenyonKR, Tutschka PJ, et al. Ocular manifesta-
tions of graft-vs-host disease. Ophthalmology. 1983;90:4-13.
5. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haemato-
poietic stem cell transplantation. Br J Ophthalmol. 1999;83:
1125-1130.
6. Saito T, Shinagawa K, Takenaka K, et al. Ocular manifestation
of acute graft-versus-host disease after allogenic peripheral
blood stem cell transplantation. Int J Hematol. 2002;75:332-334.
7. Kim SK. Update on ocular graft versus host disease. Curr Opin
Ophthalmol. 2006;17:344-348.8. Anderson NG, Regillo C. Ocular manifestations of graft versus
host disease. Curr Opin Ophthalmol. 2004;15:503-507.
9. Fijnheer R, Hettinga YM, Verdonck LF, Fijnheer R,
Rijkers GT, Rothova A. Anterior uveitis: a manifestation of
graft-versus-host disease. Ophthalmology. 2007;114:794-797.
10. Balaram M, Rashid S, Dana R. Chronic ocular surface disease
after allogeneic bone marrow transplantation. Ocular Surface.
2005;3:203-211.
11. OgawaY,MasatakaKuwanaMD.Dryeyeas amajor complication
associatedwith chronic graft-versus-host disease after hematopoi-
etic stem cell transplantation. Cornea. 2003;22:S19-S27.
12. MurphyPT,SivakumaranM,FahyG, et al. Successful use of top-
ical retinoic acid in severe dry eye due to chronic graft-versus-
host disease. Bone Marrow Transplant. 1996;18:641-642.
13. Rocha EM, Pelegrino FS, de Paiva CS, et al. GVHD dry eyes
treated with autologous serum tears. Bone Marrow Transplant.
2000;25:1101-1103.
14. Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of
dry eye in two patients with chronic graft-versus-host disease
with systemic administration of FK506 and corticosteroids.
Cornea. 2001;20:430-434.
15. Hirst LW, Jabs DA, Tutschka PJ, et al. The eye in bone marrow
transplantation. I. Clinical study. Arch Ophthalmol. 1983;101:
580-584.
16. Jabs DA, Wingard J, GreenWR, et al. The eye in bone marrow
transplantation. III. Conjunctival graft versus host disease. Arch
Ophthalmol. 1989;107:1343-1348.
17. Rojas B, Cuhna R, Zafirakis P, et al. Cell populations and adhe-
sion molecules expression in conjunctiva before and alter bone
marrow transplantation. Exp Eye Res. 2005;81:313-325.
18. Hassan AS, Clouthier SG, Ferrara JL, et al. Lacrimal gland
involvement in graft-versus-host disease: a murine model. Invest
Ophthalmol Vis Sci. 2005;46:2692-2697.
19. ShulmanHM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis
of chronic graft-versus-host disease: National Institutes of Health
Consensus Development Project on Criteria for Clinical Trials
inChronicGraft-versus-hostdisease:National Institutes ofHealth
Consensus Development Project on Criteria for Clinical Trials
in Chronic Graft-versus-Host Disease: II. Pathology Working
Group Report. Biol Blood Marrow Transplant. 2006;12:31-47.
20. Cooke KR, Kobzik L, Martin TR, et al. An experimental model
of idiopathic pneumonia syndrome after bone marrow trans-
plantation: I. The roles of minor H antigens and endotoxin.
Blood. 1996;8:3230-3239.
21. OgawaY,KuwanaM,YamakaziK, et al. Periductal area as the pri-
mary site for T-cell activation in lacrimal gland chronic graft-
versus-host disease. Invest Ophthalmol Vis Sci. 2003;44:1888-1896.
22. West RH, Szer J, Pedersen JS. Ocular surface and lacrimal
disturbances in chronic graft-versus-host disease: the role of
conjunctival biopsy. Aust N Z J Ophtalmol. 1991;19:187-191.
